KEYWORDS: Psilocybin, psilocin, indolealkylamine, hallucinogen, psychedelic, magic mushrooms, mushrooms, O-acetylpsilocin, indocybin I. INTRODUCTION Psilocybin, a tryptamine alkaloid, is found in a family of mushroom-forming fungi that when ingested can cause hallucinations. 48,49 Synergistic reactions, heightening the psychedelic effects of psilocybin, are to be expected when used in combination with other psychedelics or drugs inhibiting the metabolism of psilocybin.

Psilocybin: from ancient magic to modern medicine Scheme 1 Total chemical synthesis of psilocybin Scheme 2 Modified synthesis of psilocybin from psilocin reported by Kargbo et al. Clinical studies with psilocybin Following the identification and synthesis of psilocybin, in 1960 Sandoz Pharmaceuticals began distributing tablets containing 2 mg of psilocybin under the trade name Indocybin™.

Fed-batch fermentation leads to improved psilocybin production To demonstrate industrial applicability of psilocybin production in S. cerevisiae , controlled fed-batch fermentation was performed with the top producing strain. During fed-batch fermentation of the top psilocybin producing strain ST9482 a decrease in psilocin and corresponding increase in psilocybin titer was observed after 139h suggesting that in vivo PcPsiK is catalyzing the conversion of psilocin back to psilocybin.

Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

The results from the study demonstrated that treatment with ET-1 increased significantly the cell measurements sizes, BNP levels of the stimulated cells and decreased mitochondrial activity significantly as indicated by cell viability when compared to the non-induced NO-ET1 cells. To measure the reactive oxygen species generated by the cells induced with ET-1 and treated with the four extracts, the cells were seeded in 96 wells and deprived with serum for 18 h. Thereafter the cells were induced with ET-1 over 2 h before treated with 50 µg/mL concentrations of the four water mushroom extracts and 25 µg/mL ambrisentan for 1 h. Fluorometric Intracellular ROS assay kit MAK 143 was used according to manual instructions to detect intracellular ROS in live cells with a green fluorescence intensity at λex = 485/20520/25 nm on ET-1-induced cardiomyocytes.

After the mixture was stirred for 2 h at room temperature, H2O was added, and the mixture was evaporated in vacuo. To a suspension of lithium aluminum hydride in anhydrous tetrahydofuran under an argon atmosphere was dropwise added a solution of 6 in anhydrous tetrahydofuran over 2 h, and then the reaction mixture was refluxed for 2 h. After cooling, anhydrous Na2SO4 powder was added, and then a solution of saturated Na2SO4 was dropwise added Notes over 1 h with stirring at room temperature.

Psilocybin, a naturally derived fungal medicine, has shown promise in treating various mental health conditions. However, as psilocybin is traditionally consumed through mushrooms in the genus Psilocybe, there is a need for a comprehensive understanding of psilocybin-producing fungi to ensure consumer safety in the forthcoming adoption of new psilocybin-assisted therapeutic practices. This paper examines the biology, diversity, and ethnomycological uses of psilocybin-producing fungi, as well as recent research focused on elucidating psilocybin biosynthetic production pathways and their evolutionary history. The authors also discuss current research on psilocybin therapies and outline recommendations for necessary future mycological research. The Nagoya protocol, which protects genetic resources and traditional knowledge, pertains to psilocybin fungi, emphasizing the importance of understanding these fungi and their potential medicinal uses.

Panel A: reactions with PsiD, PsiK, and PsiM. B: reaction with 6-methylnorbaeocystin and PsiM, SAH nucleosidase, and adenine deaminase. As PsiM's substrate specificity is largely determined by the additional non-conserved structure parts that cannot be reliably modeled, any in silico substrate docking based on a homology model remains speculative, and a structural basis for the different activities of PsiM for 6-substituted tryptamines versus non- or 4-substited tryptamines remains elusive.

Researchers have successfully engineered a strain of yeast to produce psilocybin and other tryptamine derivatives that can be used to treat a range of psychological and neurological disorders. Psilocybin, the main psychoactive ingredient in magic mushrooms, has shown promise in clinical trials as a treatment for depression, anxiety, and addiction. The scientists achieved the de novo biosynthetic production of psilocybin and related tryptamine derivatives in Saccharomyces cerevisiae by expressing a pathway sourced from the fungus Psilocybe cubensis, with the addition of a cytochrome P450 reductase from the same species. The team then achieved improved production titers and rational engineering in a final production strain that produced 627 mg/L of psilocybin and 580 mg/L of the dephosphorylated degradation product psilocin in triplicate controlled fed-batch fermentations. The researchers also demonstrated the biosynthetic production of the natural tryptamine derivative aeruginascin and the production of a new-to-nature tryptamine derivative, N-acetyl-4-hydroxytryptamine. These findings could pave the way for biotechnological production of psilocybin for pharmaceutical applications and the biosynthetic production of other tryptamine derivatives of therapeutic relevance.

The results from the study demonstrated that treatment with ET-1 increased significantly the cell measurements sizes, BNP levels of the stimulated cells and decreased mitochondrial activity significantly as indicated by cell viability when compared to the non-induced NO-ET1 cells. To measure the reactive oxygen species generated by the cells induced with ET-1 and treated with the four extracts, the cells were seeded in 96 wells and deprived with serum for 18 h. Thereafter the cells were induced with ET-1 over 2 h before treated with 50 µg/mL concentrations of the four water mushroom extracts and 25 µg/mL ambrisentan for 1 h. Fluorometric Intracellular ROS assay kit MAK 143 was used according to manual instructions to detect intracellular ROS in live cells with a green fluorescence intensity at λex = 485/20520/25 nm on ET-1-induced cardiomyocytes.